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Background: Cardiovascular magnetic resonance (CMR) has favorable characteristics for diagnostic evaluation and
risk stratification of patients with known or suspected CAD. CMR utilization in CAD detection is growing fast.
However, data on its cost-effectiveness are scarce. The goal of this study is to compare the costs of two strategies
for detection of significant coronary artery stenoses in patients with suspected coronary artery disease (CAD): 1)
Performing CMR first to assess myocardial ischemia and/or infarct scar before referring positive patients (defined as
presence of ischemia and/or infarct scar to coronary angiography (CXA) versus 2) a hypothetical CXA performed in
all patients as a single test to detect CAD.
Methods: A subgroup of the European CMR pilot registry was used including 2,717 consecutive patients who
underwent stress-CMR. From these patients, 21% were positive for CAD (ischemia and/or infarct scar), 73% negative,
and 6% uncertain and underwent additional testing. The diagnostic costs were evaluated using invoicing costs of
each test performed. Costs analysis was performed from a health care payer perspective in German, United
Kingdom, Swiss, and United States health care settings.
Results: In the public sectors of the German, United Kingdom, and Swiss health care systems, cost savings from the
CMR-driven strategy were 50%, 25% and 23%, respectively, versus outpatient CXA. If CXA was carried out as an
inpatient procedure, cost savings were 46%, 50% and 48%, respectively. In the United States context, cost savings
were 51% when compared with inpatient CXA, but higher for CMR by 8% versus outpatient CXA.* Correspondence: Karine.Moschetti@chuv.ch
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management option for patients with suspected CAD.
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European Cardiovascular Magnetic Resonance registryBackground
In many countries, cardiovascular disease remains the
nation’s most important killer of men and women, causing
more than 40% of all deaths in the United Kingdom, 36%
in United States and 33% in Switzerland [1-4]. The eco-
nomic burden of CAD is vitally important also. For in-
stance, the total direct and indirect costs of CAD and
stroke were estimated at $ 156 billion in the United States
for 2008 and at £ 30.7 billion in the United Kingdom for
2006 [1,5]. In Germany, the total number of invasive cor-
onary angiography (CXA) performed in 2008 accounted
for reimbursement costs of over 500 Mio. Euros [6].
Presently, cardiovascular magnetic resonance (CMR) has
emerged as a robust, reliable and safe imaging technique
for evaluation of myocardial ischemia and infarct scar with
high sensitivity and specificity [7-16]. Prognosis in patients
with a negative, i.e. normal perfusion-CMR, is excellent
with major adverse cardiac event rates as low as 0.3–1.1%/
year [17-19]. Thus, CMR is increasingly used in daily rou-
tine in many hospitals. While CXA still remains the “gold
standard” for evaluation of CAD in many countries, Patel
et al. found 62% of elective CXA examinations to be nega-
tive for CAD (defined as <50% diameter stenoses) in a
large sample of approximately 400,000 US-patients without
known CAD [20]. Similarly, in Switzerland in 2010, about
two thirds of the CXA tests performed were negative for
CAD [21]. In Germany in 2008, only 35% of patients were
treated by percutaneous coronary interventions (PCI) and
another 7.5% by bypass surgery after CXA [22]. In the
United Kingdom, the last available figures on hospitals
activities enable to estimate that more than 58% of the
performed CXA tests did not lead to invasive cardiac pro-
cedures (PCI or CABG) afterwards [1,23]. This suggests
that for a considerable number of patients, CXA may not
be appropriate. In addition, CXA has some disadvantages
such as exposure to radiation, bleeding, and contrast
nephropathy.
In a few single centre studies, cost savings were found
when using CMR versus conventional CXA strategies
for evaluation of chronic and acute ischemic heart dis-
ease [24,25]. While such preliminary studies are promis-
ing, further investigations are required to better describe
the economic impact of CMR utilization. There is gen-
eral agreement that randomized controlled trials (RCT)
are important tools to test hypotheses in a well defined
and controlled environment. Once the efficacy of a novel
treatment, procedure, or diagnostic test has beendemonstrated in a RCT, the question remains whether
the same performance will be achieved when applied in
a broad community, i.e. in the majority of the health
care services. Thus, RCT can answer the question
whether a given test or treatment will outperform others
in an ideal world, while a registry is the adequate setting
to demonstrate in the real-world whether a given test or
treatment is still performing as predicted, and conse-
quently, it also appears appropriate to analyze costs gen-
erated in a registry environment [26]. In the current
study, therefore, a costs analysis was performed in the
multicenter European CMR registry [27,28] comparing
two strategies for the detection of significant coronary
artery stenoses in suspected CAD. CMR was used to as-
sess myocardial ischemia and scar as a first step before
referring CAD-positive patients to CXA. Costs were
then compared with a second “hypothetical” strategy,
where all patients undergo CXA as a single test to detect
CAD. This study aimed at assessing the respective costs
of these two strategies from a health care payer perspec-
tive in the German, United Kingdom, Swiss, and United
States health care systems.
Methods
Patient population
We used data from the European CMR pilot registry, a
multicenter registry including 20 German hospitals and
a total of 11,040 consecutive patients with different indi-
cations for CMR scans [27]. The most frequent indica-
tions were work-up of myocarditis/cardiomyopathies
(n = 3,511), risk stratification in suspected CAD/ischemia
(n = 3,399), as well as assessment of cardiac muscle via-
bility (n = 1,126). The present analysis focused on
patients with clinically suspected CAD who had a stress
CMR test. After exclusion of patients with CXA prior to
the CMR examination (n = 682), the study population
was composed of 2,717 patients (64.4% male gender;
mean age 62.4 ± 11.7 years).
The analysis of the CMR examination was done on-
site, as was the decision to proceed to revascularization
or not, or to add further testing. Centers were instructed
to follow established algorithms to assess ischemia, i.e.
appearance of ≥1 hypokinetic (or worsening) segment
during dobutamine-CMR [11,18] or ≥1 hypoperfused
segment(s) during vasodilator induced perfusion-CMR
residing in viable (late enhancement negative) tissue
[10,13,18,29].
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or transmural scar being compatible with CAD [10]. Of
the 2,717 patients, 69% underwent adenosine perfusion-
CMR and 31% a dobutamine stress-CMR scan. Patients
diagnosed positive for ischemia and/or scar by CMR had a
CXA. No other test was performed in patients negative for
myocardial ischemia and/or scar. Among the study group,
the proportion of patients diagnosed positive for CAD was
21%, uncertain 6%, and negative 73% after CMR scan (see
Figure 1). Those with uncertain diagnosis had additional
tests (85% stress echocardiography (SEcho), 13% cardiac
CT, 2% SPECT) (see Figure 1).
Costs of the different procedures - Definitions
The analysis was performed from a health care payer per-
spective using 2011 unit costs data in Euros (€) for Ger-
many, pounds (£) for the United Kingdom, Swiss Francs
(CHF) for Switzerland, and American Dollars (US$) for
the United States. In the following sections, definitions
and descriptions of the health care systems in Germany,
the United Kingdom, Switzerland, and the United StatesFigure 1 The two management strategies of the patients. a)
CMR as a “gate keeper” followed by CXA in case of presence of
myocardial ischemia b) “Hypothetical” CXA in all patients with
suspected CAD.are given to explain how the unit costs of tests included in
the analysis were derived for each country.
Germany
The German health care system relies on public and pri-
vate health insurers systems. Approximately 90% of the
population holds a public insurance policy, the remaining
10% holds a private insurance policy [30]. Costs gener-
ated in the private sector were not analyzed in this study.
Public insurance services for outpatient procedures are
charged based on a uniform value scale [31]. Inpatient
procedures are charged based on the diagnosis related
groups (DRG) payment system [32].
In our analyses, SEcho, cardiac CT, and SPECT tests
were considered as outpatient tests, while CXA prices were
calculated for both, outpatient and inpatient situations.
CMR is not yet coded as a specific outpatient examination
in the public sector in Germany. In the absence of an out-
patient CMR tariff, we opted to use the thoracic MR exam-
ination and its related costs as a substitute for the CMR
test for the calculations. If a CMR examination is per-
formed in a public hospital, it leads to an admission like all
inpatient procedures. However, the patient discharge is
done the same day avoiding the hospital stay (e.g. by yield-
ing a normal test result). The CMR test is then reimbursed
with a specific code in the public sector (=pre-inpatient
test). CMR tests performed as an inpatient procedure in
the public sector are covered by the respective DRG.
The United Kingdom
The UK National Health Service (NHS) covers all legal
residents of the United Kingdom. Primary care services
are provided by general practitioners (GP) and hospitals,
mainly publicly owned, deliver care to patients referred
by GP. Each care event is assigned to a Healthcare Re-
source Group (HRG) which is a grouping of care events
supposed to consume a similar level of resources.
With the exception of the CMR, the costs of the different
diagnostic procedures were derived by combining 3 refer-
ences: the list of procedure codes (OPCS 4.5) with detailed
description [33], the national HRGs grouper [34], and the
2009/2010 Reference costs that provide the national aver-
age costs for each HRG [23]. For years, CMR (OPCS=
U10.3) has been to map to MRI codes with an associated
reimbursement (£ 170) that does not match with the costs
of CMR. In a transition phase, new procedure codes with
higher tariffs/costs are about to be implemented for the
CMR in the NHS. We chose to use the new tariff/cost that
was suggested by the British Society of Cardiovascular
Magnetic Resonance (BSCMR) and the British Society of
Cardiovascular Imaging (BSCI).
CMR as well as SEcho, cardiac CT, and SPECT exami-
nations were outpatient tests, while CXA was considered
as either an outpatient or inpatient procedure.
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The Swiss health care system relies on a public health in-
surance system. Regulated by the Federal Health Insurance
Law (LAMal), this system consists of competing private
health plans to which each resident in Switzerland is
obliged to enroll. These health plans cover the whole range
of medical services. Individuals can add private supplemen-
tary insurance to fund any additional health care [35].
The costs of all outpatient procedures are coded in the
TARMED [36] system and for inpatient procedures a DRG
payment system is already implemented in some hospitals
in Switzerland, and has been launched in all Swiss hospitals
since January 1, 2012. Inpatient unit costs (based on DRGs)
were derived for this study from the University Hospital of
Lausanne (CHUV), where the DRG system is already
implemented.
CMR examinations such as SEcho, cardiac CT, and
SPECT were considered as outpatient tests, while costs
for CXA were calculated as either outpatient or inpatient
procedure.
The United States
The costs generated by the different diagnostic proce-
dures in the United States were calculated based on an
average national reimbursement as listed in the Current
Procedural Terminology codes (CPT) and Clinical Clas-
sifications Software version 2011 [37]. For the CXA,
CMR, SEcho, SPECT, and cardiac CT performed as out-
patient procedures, the respective CPT codes were used.
The inpatient CXA cost was calculated by adding the
cost of the outpatient CXA procedure and the cost of a
hospital stay of one day. The cost of a hospital stay in a «
floor bed » for one day was derived from a recent publi-
cation reporting the hospitalization costs in the Medi-
care system [38,39]. All costs were converted to 2011 US
dollars using the consumer price index (www.bls.gov).
Costs compilations
The average cost per patient for the two strategies was cal-
culated by using the proportion of patients in the different
branches of the diagram (Figure 1) and the unit costs of
the different tests performed (Table 1). Compilations were
performed for the various situations described above.Table 1 Unit costs of the tests performed in Germany, in the
Unit
costs
Outpatient
in Germany
(€)
Inpatient in
Germany
(€)
Outpatient in the
United Kingdom
(£)
Inpatient in
United King
(£)
CXA 588 1,207 1,055 1,934
CMR 164* 393** 558
SEcho 94 / 213
CT 165 / 111
SPECT 275 / 406
* Cost for a thoracic MR examination. ** Cost for MR as a pre-inpatient examinationAs shown in Table 1, large differences exist between
the unit costs of the different tests when performed in
Germany, the United Kingdom, Switzerland, or the Uni-
ted States. Swiss costs are 1.3 to 3.5 times higher than
public United States costs, 2.5 to 4 times higher than the
German costs and 1.4 to 3 times higher than the United
Kingdom costs for the outpatient tests. In terms of
country ranking, this is in accordance with the 2010
International Federation of Health Plans [40] report,
which provides actual costs for common medical ser-
vices across 12 countries. Each health care system has its
own organization and specificities, and explaining such
differences is beyond the scope of this study. DRG prices
for inpatient CXA include the costs of the medical pro-
cedures as well as the “hotel costs” associated with the
hospital stay. The different components of the total cost
were not analyzed here, since the analysis was performed
from a health care payer perspective.
Results
Cost analysis
Tables 2, 3, 4 and 5 provide the average costs per patient
for the two strategies in the various situations in the 4
countries. Figure 2 displays the percentage of cost varia-
tions for the various situations in the 4 countries.
Situation in Germany
Using costs currently covered by the public health insur-
ance system for the outpatient CMR test, the CMR strat-
egy is 50% less costly than the CXA outpatient strategy
(Table 2). When the CMR test is performed by public hos-
pitals as a pre-inpatient test and CXA as an outpatient
test, the CMR strategy still remains less costly by 11%.
If CXA is performed as an inpatient procedure (with
“hotel costs” included), CMR gate keeping strategy per-
formed as a pre-inpatient test or outpatient test is again
less costly by 46% and 65%, respectively.
Situation in the United Kingdom
Using the average costs of the procedures calculated
across 400 NHS care providers and the CMR costs that
will be used in the near future, the CMR strategy is 25%
less costly than the CXA outpatient strategy (Table 3). IfUnited Kingdom, Switzerland, and in the United States
the
dom
Outpatient in
Switzerland
(CHF)
Inpatient in
Switzerland
(CHF)
Outpatient in
the United
States (US$)
Inpatient in
the United
States (US$)
2,580 4,638 874 2,652
1,420 / 740 /
447 / 303 /
494 / 446 /
2,183 / 570 /
.
Table 2 Costs related to the two strategies for different situations in Germany
Costs per patient in different situation in € CMR strategy “hypothetical” CXA strategy
All tests performed as outpatient procedures in Germany 292* 588
CXA as an inpatient test in Germany 420 1,207
CMR as pre-inpatient test and CXA outpatient test in Germany 521 588
CMR as pre-inpatient test and CXA as an inpatient test in Germany 649 1,207
* Code, i.e. cost for a thoracic MR examination used for calculations.
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spending one night at the hospital), the reduction in
costs amounts to almost 51% in favor of the CMR
strategy.
Situation in Switzerland
When CXA is performed as an outpatient test, CMR
strategy costs 23% less than the CXA strategy (Table 4).
If the CXA procedure is performed as an inpatient test
(i.e. spending one night at the hospital), the reduction in
costs amounts to 48% in favor of the CMR strategy.
Situation in the United States
In contrast to the previous situations, the CMR strategy
costs 8% more than the CXA strategy when all tests are
performed as outpatient procedures in the United States
(Table 5). Opposite results are found if the CXA proced-
ure is performed as an inpatient test. In this case, the
CMR strategy generates a costs reduction of 50% com-
pared with the CXA strategy.
Breakeven analysis
Based on the proportions given in Figure 1, a breakeven
analysis was performed in order to assess at which price
the CMR strategy would be cost neutral for diagnostic
work-up of public outpatients with suspected CAD, i.e.
if all tests are performed on an outpatient basis.
For the German system, the results of this analysis
suggest that the CMR strategy would be costs saving up
to a reimbursement level of Euros 460, while current re-
imbursement is Euros 164 (code = outpatient thoracic
MR) and Euros 393 in public hospitals (pre-inpatient
MR). In the United Kingdom, the breakeven analysis
found that the CMR strategy would be cost neutral at a
reimbursed price of £ 825 while the suggested future
price is fixed at £ 558. In Switzerland considering that
all tests are performed as outpatient procedures, CMR
would be costs saving at a reimbursement level up toTable 3 Costs related to the two strategies for different situa
Costs per patient in different situation in £
All tests performed as outpatient procedures in the United Kingdom
CXA performed as an inpatient procedure in the United KingdomCHF 2,015, while the actual price equals CHF 1,420. In
the United States, cost savings are achieved by CMR in
comparison versus in-patient CXA (Figure 2). For this
situation, a break even for outpatient CMR is achieved
up to a reimbursement for CMR of US$ 2,085, while
current reimbursement is set to US$ 740.Discussion
While CMR is emerging as a valuable tool to study
CAD, data are still rare on costs and cost-effectiveness
of this approach versus a conventional invasive CXA
strategy to identify patients in need of revascularization.
In a recent study conducted in the setting of acute chest
pain, Miller et al. found a reduction of hospitalization
costs by 23% when using a CMR strategy in an observa-
tional unit in the Emergency Department versus an in-
patient strategy [25]. Of note, the outcome of the
patients was not different for the two approaches, while
a large percentage of patients could leave the hospital
early when CMR results excluded an acute coronary
syndrome [25]. Furthermore, the 1-year costs subse-
quent to discharge were lower for the CMR patients ver-
sus the inpatient admissions [41].
In the current study, we were interested in costs gen-
erated by a CMR approach applied in non-emergency
situations versus a conventional invasive CXA approach.
For this purpose, data from the European CMR pilot
registry were used. In this setting, the patient pathway
after CMR examination is reported in a routine clinical
environment, which is advantageous, if management
costs are to be calculated as disease prevalence has a
major influence on cost and cost-effectiveness calcula-
tions. In the present setting, every positive CMR exam-
ination required an additional invasive CXA study to
confirm the presence of stenoses and to depict its anat-
omy, which is a prerequisite to percutaneous or opera-
tive treatment of such lesions. Thus, with an increasing
prevalence of relevant stenoses in the populationtions in the United Kingdom
CMR strategy “hypothetical” CXA strategy
789 1,055
970 1,934
Table 4 Costs related to the two strategies for different situations in Switzerland
Costs per patient in different situation in CHF CMR strategy “hypothetical” CXA strategy
All tests performed as outpatient procedures in Switzerland 1,984 2,580
CXA performed as an inpatient procedure in Switzerland 2,408 4,638
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rise. Taking this into account, the utilization of registry
data is of great value, as it reflects a real world pre-test
prevalence. The data also show a high percentage of ap-
proximately 60% of patients being deferred from further
testing after a gate keeper CMR examination when per-
formed in a population with a realistic pre-test preva-
lence. This is in line with other studies that yielded
approximately 70% of normal CXA studies [20]. In this
context, it should be noted, that CMR is not recom-
mended as a first-line gate keeper test in patients with
acute ischemia, e.g. with evidence for acute MI with or
without ST elevations.
In addition, it should be recognized that a CMR test
yields additional information beyond the presence of
myocardial ischemia and scar. CMR allows for quantifi-
cation of left and right ventricular function, valve func-
tion, myocardial viability, and 3D angiography may also
be integrated in a CMR examination. In addition, the
European CMR registry also yielded strong data under-
lining the safety of ischemia testing by CMR [42].
The German health care system
In the German public health care system, the study
shows that the utilization of CMR as first non-invasive
imaging test in the diagnostic work-up of patients with
suspected CAD costs less compared with an invasive
CXA strategy. As shown in Figure 2, considerable sav-
ings could be expected since approximately 865,000 in-
vasive CXA examinations were performed in Germany
in 2009, of which 88% were inpatient procedures [6].
The United Kingdom health care system
Using the CMR as first non-invasive imaging test in the
diagnostic work-up of patients with suspected CAD is
less costly than using the invasive CXA strategy. Like in
Germany and Switzerland (see below), CMR may have a
gatekeeper role to invasive examinations in the United
Kingdom. A relevant gatekeeper function is highly likely
in view of the last available figures in the United King-
dom that tend to show that more than 58% of the per-
formed CXA gave normal results [23].Table 5 Costs related to the two strategies for different situa
Costs per patient in different situation in US $
All tests performed as out-patient procedures in the United States
CXA performed as an inpatient procedure in the United StatesThe Swiss health care system
For Switzerland, the study shows that the utilization of
CMR as the first non-invasive imaging test in the work-
up of patients with suspected CAD results in lower costs
compared with CXA to all patients and this holds for
both, the inpatient and outpatient CXA situation. This
suggests a potential role of CMR as a gatekeeper for in-
vasive examinations in Switzerland. The cost saving ef-
fect is primarily the result of a reduced number of CXA
as approximately 73% of patients in the European CMR
registry were deferred from further invasive testing after
the CMR examination. In Switzerland the rate of normal
CXA studies ranged between 55 to 66% over the last
3 years [21].
The United States health care system
Data from 2006 demonstrate that approximately two
thirds of all cardiac catheterizations were performed on
an in-patient basis in the United States [43,44].
Thus, utilization of CMR as a gatekeeper for inpatient
CXA could lead to substantial costs reduction in the
work-up of patient with suspected CAD.
Limitations
The proportion of patients undergoing various tests may
vary for other populations than the ones we studied.
Also, in the United States, the unit costs for the cardiac
tests may vary substantially between different geograph-
ical regions, and therefore the results are representative
for the entire health care system under study, but not
for smaller geographical regions.
In this study, the cost analysis was performed from a
health care payer perspective. An analysis with a broader
perspective would include other costs associated with
the diagnostic procedures such as complications and po-
tential future risks induced by CXA radiations for in-
stance, as well as patients’ outcomes. Such an extended
analysis could be more relevant to policy makers gener-
ally interested in the implications from a societal point
of view.
In these registry data, the outcome of the patients de-
ferred from CXA is not known. However, there istions in the United States
CMR strategy “hypothetical” CXA strategy
942 874
1,308 2,652
Figure 2 Percentage of cost variation between CMR strategy and CXA strategy. When all tests are performed as outpatient procedures in
Germany the CMR strategy is 50% less costly than the CXA strategy. By contrast, when all tests are performed as inpatient procedures in the
United States, CMR strategy is 8% more costly than the CXA strategy.
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CMR ischemia testing. In a cohort of 513 patients with
suspected or known CAD, the event rates for cardiac
death and non-fatal MI in patients with a negative
perfusion-CMR or a negative stress dobutamine-CMR
were 0.7% and 1.1%, respectively [18]. In another cohort
of 405 patients, these event rates were 0.3% and 1.1% for
women and men with a negative perfusion-CMR, re-
spectively (difference not significant) [42]. Short and
intermediate term complications of the tests [45] were
not considered in the cost analysis. It was not within the
scope of this registry to evaluate and thus, to collect the
results either of the CXA examinations or of the other
alternative tests performed in the patients with inconclu-
sive CMR examinations.
In the present study, it was assumed that the final
diagnosis and thus, the decision to revascularize or not,
can be reached by coronary angiography. This strategy is
still the predominant one in many hospitals. However,
there is increasing debate whether the hemodynamic sig-
nificance of coronary lesions should be assessed e.g. by
fractional flow reserve (FFR) to allow for a better clinical
decision making [46]. In the current analyses costs were
considered for invasive CXA only and no costs for an in-
vasive ischemia testing e.g. by FFR, were added. Thus,
the costs for the invasive arm are potentially underesti-
mated. Conversely, for the CMR strategy, information
on both ischemia and coronary anatomy was obtained in
all ischemia-positive patients.
One might criticize the design which allocated all patients
to an invasive procedure in the CXA arm. Whether thepre-test likelihood for having CAD was sufficient to justify
an invasive diagnostic procedure in all patients is not
known. However, data from Switzerland and the United
States show a large proportion of 60%–70% of patients
undergoing CXA being negative for CAD, which indicates
that in general clinical practice patients with a low to inter-
mediate pre-test likelihood for CAD are indeed sent to
CXA. Interestingly, in our study, the negative rate for CAD
after the CMR gatekeeper examination was 73%.
One might also criticize that the study compared two
strategies for the diagnostic management of CAD with-
out considering other tests. Indeed, other tests such as
cardiac CT [47], SEcho, or SPECT when used as a first
test may also play an important gate keeper role to
CXA. However, the European CMR registry data deal
with CMR as a first test and therefore, cannot be used
to address other methods as potential gatekeepers.Conclusions
This cost analysis performed in a multicenter setting
suggests that the development of the use of CMR
should be further explored as a management option for
patients with suspected CAD. Indeed, it might imply
some reductions in the number of CXA examinations
and consequently might lead to costs savings together
with improved patient safety and comfort. In the con-
text of limited resources in the health care system and
the need to permanently optimize their allocation,
CMR may lead to a better utilization of resources at
the hospital level.
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